Sputnik Light has already been registered in more than 20 countries as a standalone vaccine
A preliminary laboratory study conducted by the Gamaleya Center has demonstrated that the Sputnik V vaccine and the one-shot Sputnik Light booster (based on human adenovirus serotype 26, the first component of Sputnik V) are effective against Omicron (B.1.1.529) variant of COVID, providing for better protection when compared to other vaccines.
Heterologous boosting with Sputnik Light is the solution to increase other vaccines’ efficacy, including against Omicron, and extend the booster protection period.
Sputnik Light as a booster significantly increases virus neutralising activity against Omicron based on sera 2-3 months after revaccination and is a universal booster to other vaccines inducing stronger antibody and T-cell response.
The efficacy of mRNA vaccines has proven to be waning, demonstrated by a number of scientific publications. A Swedish study in The Lancet journal[iv] has shown that the Pfizer vaccine’s efficacy against Delta is falling to 47 per cent after four months, to 29 per cent after six months and to 23 per cent after seven months. A recent study in the US among 65+ years olds demonstrated the decrease in mRNA vaccine effectiveness accelerating against Delta after month four, reaching a low of approximately 20 per cent in months five through seven.
Recognising the waning efficacy of mRNA vaccines, the EU, the UK, Greece, South Korea and other countries have recommended reducing the boosting period from six to three months.
Sputnik Light has already been registered in more than 20 countries as a standalone vaccine and a universal booster to other vaccines helping to increase their efficacy (including in Argentina, the UAE, Bahrain, Philippines, and San Marino). Sputnik V has been authorised in 71 countries with a total population of over 4 billion people.
Sputnik Light has already shown strong results used as a booster in mix and match trials in Argentina. A combination of Sputnik Light with vaccines produced by AstraZeneca, Sinopharm, Moderna and Cansino, conducted in 5 provinces (City and Province of Buenos Aires, as well as Córdoba, La Rioja and San Luis) has demonstrated that Sputnik Light induces stronger antibody and T-cell response as compared to the homologous regimen (two shots of the same vaccine).
